May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Aldose Reductase Inhibitor Fidarestat Alleviates Diabetes–Induced Retinal Oxidative–Nitrosative Stress and Poly(ADP–Ribose) Polymerase Activation
Author Affiliations & Notes
  • I.G. Obrosova
    Division of Nutrition and Chronic Disease, Pennington Biomedical Research Center of the Louisiana State University System, Baton Rouge, LA
    Internal Medicine, University of Michigan, Ann Arbor, MI
  • C. Szabo
    Research Dept., Inotek Pharmaceuticals Corp., Beverly, MA
  • M.J. Stevens
    Internal Medicine, University of Michigan, Ann Arbor, MI
  • P. Pacher
    National Institute of Alcohol Abuse and Alcoholism, NIH, Bethesda, MD
  • Footnotes
    Commercial Relationships  I.G. Obrosova, Sanwa Kagaku Kenkyusho Co., Ltd F; C. Szabo, None; M.J. Stevens, None; P. Pacher, None.
  • Footnotes
    Support  ADA Research Grant, NIH Grant DK59809–01, JDRFI Center Grant 4–200–421
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4704. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I.G. Obrosova, C. Szabo, M.J. Stevens, P. Pacher; Aldose Reductase Inhibitor Fidarestat Alleviates Diabetes–Induced Retinal Oxidative–Nitrosative Stress and Poly(ADP–Ribose) Polymerase Activation . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4704.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Aldose reductase inhibitors (ARIs), antioxidants, and, recently, PARP inhibitors were found to prevent manifestations of diabetic retinopathy in animal models. We studied the relation among three mechanisms, by evaluating the potent and specific ARI fidarestat (F) on retinal oxidative–nitrosative stress and PARP activity in STZ–diabetic rats and high glucose–exposed endothelial cells. Methods: We used control rats and STZ–diabetic rats treated with or without F (16 mg kg–1d–1) starting from induction of diabetes. The duration of experiment was 6 wks. Sorbitol pathway intermediates were assessed by enzymatic spectrofluorometric methods, lipid peroxidation products by standard colorimetric method with N–methyl–2–phenylindole, and nitrotyrosine and PARP activity by immunohistochemistry. In in vitro studies, bovine retinal endothelial cells were cultured in 5 mM glucose, 30 mM glucose and 30 mM glucose plus 1 µM F. Oxidative–nitrosative stress was evaluated using CM–H2DCFDA and flow cytometry, and PARP activity by CELISA. Results: Retinal nitrotyrosine and poly(ADP–ribose) immunoreactivities were increased in diabetic rats vs controls. F treatment resulted in 1) normalization of sorbitol pathway activity (manifested by both sorbitol and fructose concentrations), without affecting retinal glucose concentrations; and 2) suppression of lipid peroxidation, nitrosative stress and PARP activity, in the retina of diabetic rats. In vitro, F decreased CM–H2DCFDA fluorescence (a marker of intracellular oxidative–nitrosative stress) and poly(ADP–ribose) accumulation in high glucose–exposed endothelial cells. F did not affect poly(ADP–ribose) formation in cell–free system containing PARP and NAD. Conclusions: Aldose reductase inhibition counteracts oxidative–nitrosative stress and PARP activation, two phenomena implicated in the pathogenesis of diabetic retinopathy.

Keywords: diabetic retinopathy • oxidation/oxidative or free radical damage • pharmacology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.